Abstract:Objectives: To retrospectively compare and evaluate ablation zone volume and its reduction from baseline to 1 month follow-up post percutaneous microwave ablation (MWA) between healthy and cirrhotic liver parenchyma. Methods: Institutional database research identified 84 patients (118 hepatic tumors) who underwent percutaneous MWA with the same system. Caudal-right lobe ratio was applied to distinguish cirrhotic (n = 51) and healthy (n = 67) group; ITK-SNAP software was used to quantify ablation zone volume. Long (LAD) and short 1 (SAD-1) and 2 (SAD-2) axis, tumor size diameter (mm) and volume (cm3) of the ablation zones were evaluated for each treated lesion in both groups at baseline (immediately post ablation) and at 1 month follow-up. Results: There was no significant difference comparing ablation zone volumes at baseline (healthy group: mean ablation volume 14.84 cm3 versus cirrhotic group: mean ablation volume 17.85 cm3, p = 0.31) and 1 month post ablation (healthy group: mean ablation volume 9.15 cm3 versus cirrhotic group: mean ablation volume 11.58 cm3, p = 0.24). When both “healthy” and “cirrhotic” liver group were evaluated independently there was a significant difference of ablation volumes reduction (p-value < 0.001) from baseline to 1 month follow-up. When both groups were compared based on reduction (35.12–38.34%) there was no significant difference in ablation zone volumes (p-value = 0.77) Conclusions: Percutaneous MWA results in ablation zones of a comparable volume in both healthy and cirrhotic liver parenchyma. Both cirrhotic and healthy liver parenchyma experience a similar significant reduction of ablation zone volume at 1 month post therapy. Advances in knowledge statement: This study evaluates and compares the volume of the ablation zone after MWA between healthy and cirrhotic liver parenchyma from baseline to 1 month follow-up and attempts to identify potential differences. It is the first study to demonstrate significant shrinkage of ablation volumes in healthy livers as compared to cirrhotic livers after 4 weeks of follow up. The results of this study can help us understand the effect of MWA when applied in different backgrounds of liver parenchyma, which could lead to different treatment planning.

Risk factor for vital signs elevation during percutaneous microwave ablation of liver tumor under deep sedation

Major Complications After Lung Microwave Ablation: A Single-Center Experience on 204 Sessions

Propofol Compared to Midazolam Sedation and to General Anesthesia for Percutaneous Microwave Ablation in Patients with Hepatic Malignancies: A Single-Center Comparative Analysis of Three Historical Cohorts

Post-operative hypertension during early recovery following liver tumour ablation: A retrospective study

A randomized control study on anesthetic effects of flurbiprofen axetil combined with propofol on patients with liver cancer receiving microwave ablation

Safety of CT-Guided Microwave Ablation of Subcardiac Liver Tumors

Effectiveness of Butorphanol in alleviating intra- and post-operative visceral pain following microwave ablation for hepatic tumor: a dual-central, randomized, controlled trial

Feasibility and safety study of ultrasound-guided percutaneous microwave ablation for Sub-cardiac liver cancers without artificial ascites assistance

Percutaneous microwave ablation of hepatic tumors: is there an impact of cirrhotic liver parenchyma upon the volume and short-term assessment of the ablation zone?

Combined multiple regional anesthesia for microwave ablation of liver Tumors: Initial experience

Risk factors for lung parenchyma hemorrhage and hemoptysis during computed tomography‐guided microwave ablation in patients with stage I non‐small cell lung cancer: A bicentric retrospective study

Artificial ascites‐assisted microwave ablation for liver cancer adjacent to the diaphragm and perioperative nursing care

Analysis and prediction of ablation zone absorption in papillary thyroid microcarcinoma undergoing microwave ablation

Safety and Efficacy of Percutaneous Microwave Ablation for Post-Procedural Haemostasis: a Bi-Central Retrospective Study Focusing on Safety and Efficacy.

Precise Microwave Ablation in Hepatic Neoplasms Adjacent to High-Risk Structures: a Prospective Pilot Study

Clinical Assessment of Percutaneous Microwave Ablation for Liver Tumors Abutting Special Locations under B Ultrasound Guidance

Factors Impacting Microwave Ablation Zone Sizes: A Retrospective Analysis

Risk Factors for Hospitalization Duration Longer Than 24 Hours Following Percutaneous Radiofrequency Ablation of Liver Tumours

Analysis of technical failure after 1,613 surgical microwave ablations: A propensity score-matched analysis

Enhanced recovery after surgery for percutaneous CT-guided microwave ablation of lung tumors: A single-center retrospective cohort study

Invasive Pulmonary Aspergillosis Secondary to Microwave Ablation: a Multicenter Retrospective Study.